Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

New England Journal of Medicine

Volumn 355, Issue 7, 2006, Pages 675-684

  De Nijs, Ron N J ^a   Jacobs, Johannes W G ^a   Lems, Willem F ^b   Laan, Roland F J ^c   Algra, Ale ^a   Huisman, Anne Margriet ^d   Buskens, Erik ^a   De Laet, Chris E D ^h   Oostveen, Ans C M ^e   Geusens, Piet P M M ^f   Bruyn, George A W ^g   Dijkmans, Ben A C ^b   Bijlsma, Johannes W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

^e TWENTEBORG HOSPITAL   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MEDICAL CENTER LEEUWARDEN   (Netherlands)

^h SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; GLUCOCORTICOID; PLACEBO; PREDNISONE; 1-HYDROXYCHOLECALCIFEROL; BONE DENSITY CONSERVATION AGENT; HYDROXYCOLECALCIFEROL;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FRACTURE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; RISK FACTOR; SKIN DISEASE; TREATMENT OUTCOME; VERTEBRA MALFORMATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MIDDLE AGED; SPINE;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; MIDDLE AGED; OSTEOPOROSIS; RHEUMATIC DISEASES; SPINE;

EID: 33747363453     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa053569     Document Type: Article

References (32)

1. de Nijs RN, Jacobs JW, Bijlsma JW, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:1375-83.
2. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
3. Vestergaard P, Olsen ML, Paaske Johnsen S, Rejnmark L, Sorensen HT, Mosekilde L. Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med 2003;254:486-93.
4. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-6.
5. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002;966:73-81.
6. Klein RG, Arnaud SB, Gallagher JC, DeLuca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism: role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 1977;60:253-9.
7. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32:151-6.
8. Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002;87:4033-41.
9. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
10. Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993;20:1666-9.
11. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
12. Sato F, Ouchi Y, Okamoto Y, et al. Effects of vitamin D2 analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3-E1 osteoblastic cells. Res Exp Med (Berl) 1991;191:235-42.
13. Shiraishi A, Takeda S, Masaki T, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000;15:770-9.
14. Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999;9:75-81.
15. Ringe JD, Coster A, Meng T, Schacht E, Umbach R. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 1999;65:337-40.
16. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D(3) analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004;15:589-602.
17. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.
18. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997;61:382-5.
19. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
20. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
21. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003;18:919-24.
22. Kovac D, Lindic J, Kandus A, Bren AF. Prevention of bone loss in kidney graft recipients. Transplant Proc 2001;33:1144-5.
23. Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001;16:2111-7.
24. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003;76:1498-502.
25. Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004;350:767-76.
26. Kleerekoper M, Parfitt AM, Ellis BI. Measurements of vertebral fracture rates in osteoporosis. In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL, eds. Proceedings of the Copenhagen International Symposium on Osteoporosis June 3-8. Copenhagen: Aalberg Stiftsbogtrykkeri, 1984:103-9.
27. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973;4:643-6.
28. Pearce G, Ryan PF, Delmas PD, Tabensky DA, Seeman E. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998;37:292-9.
29. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 1999;65:317-27.
30. Aerssens J, van Audekercke R, Talalaj M, et al. Effect of 1 alpha-vitamin D3 on bone strength and composition in growing rats with and without corticosteroid treatment. Calcif Tissue Int 1994;55:443-50.
31. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-74.
32. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002;109:1041-8.